Schedule of Net (Loss) Income Per Share |
The following tables set forth the computation of basic and diluted net (loss) income per share of common stock for the three and nine months ended September 30, 2023 and September 30, 2022 (in thousands, except share and per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
2023 |
|
2022 |
Basic (loss) income per share: |
|
|
|
|
Net (loss) income |
|
$ |
(5,228) |
|
|
$ |
3,192 |
|
Weighted average shares |
|
46,764,117 |
|
|
9,413,466 |
|
Basic net (loss) income per share |
|
$ |
(0.11) |
|
|
$ |
0.34 |
|
|
|
|
|
|
Diluted (loss) income per share: |
|
|
|
|
Net (loss) income |
|
$ |
(5,228) |
|
|
$ |
3,192 |
|
Weighted average shares - basic |
|
46,764,117 |
|
|
9,413,466 |
|
Effect of dilutive securities: |
|
|
|
|
Potentially dilutive shares |
|
— |
|
|
166 |
|
Weighted average shares - diluted |
|
46,764,117 |
|
|
9,413,632 |
|
Diluted net (loss) income per share |
|
$ |
(0.11) |
|
|
$ |
0.34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
|
2023 |
|
2022 |
Basic and diluted loss per share: |
|
|
|
|
Net loss |
|
$ |
(23,376) |
|
|
$ |
(31,846) |
|
Weighted average shares |
|
24,281,306 |
|
|
9,404,679 |
|
Basic and diluted net loss per share |
|
$ |
(0.96) |
|
|
$ |
(3.39) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of Anti-dilutive Securities |
The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three and nine months ended September 30, 2023 and 2022, as they could have been anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three and Nine Months Ended |
|
|
September 30, |
|
|
2023 |
|
2022 |
Stock options |
|
1,849,229 |
|
1,260,906 |
Warrants on common stock1
|
|
4,136,990 |
|
366,990 |
Restricted Stock Units |
|
— |
|
— |
1 The weighted average number of common shares outstanding includes the weighted average outstanding pre-funded warrants for the period because their exercise price was nominal. There were no pre-funded warrants outstanding as of September 30, 2023.
|